Clinical Programs. The preclinical and clinical trials conducted by or on behalf of the Company that are described in the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in all material respects in accordance with procedures and controls pursuant to accepted professional scientific standards and all applicable local, state and federal and foreign laws, rules, regulations and published guidance, including, but not limited to, the Federal Food, Drug and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312. The descriptions of the results of such studies, tests and trials contained in the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects. Other than as described in the Pricing Disclosure Package, the Company is not aware of any studies, tests or trials the results of which reasonably call into question the clinical trial results described or referred to in the Prospectus when viewed in the context in which such results are described and the clinical state of development. Other than as described in the Pricing Disclosure Package, in the past five years, the Company has not received any written notices or correspondence from the U.S. Food and Drug Administration or any foreign, state or local governmental body exercising comparable authority, including the European Medicines Agency (collectively, the “Regulatory Authorities”) requiring the termination or suspension of any preclinical or clinical trials conducted by or on behalf of the Company. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the Regulatory Authorities or that additional studies, tests or preclinical or clinical trials will reach similar results or conclusions.
Clinical Programs. If Client participates in a Clinical Program(s), Client shall:
Clinical Programs. As of the Effective Date of this Contract, Contractor shall provide all of the Clinical Programs listed in Exhibit S, Standard Programs, and all of the programs listed in this Section 3.3.3 and are hereby made available to HCA, Members, and the Members’ providers, as appropriate. Such programs will be reviewed by the parties and updated on an annual basis.
Clinical Programs. As consideration for the clinical Services selected by County in accordance with the Agreement, County will pay to Contractor the fees set forth below: Base Clinical Services (included in base administrative fee) Concurrent DUR No Charge Inform Prescribing Program No Charge Quantity level limit (QLL) system edits & support No Charge Prior authorization (PA) system edits & support No Charge Duration of therapy edits & support No Charge Therapeutic interchange (as required) No Charge Quarterly clinical program reporting No Charge Additional Clinical Programs: If the County selects any of the following additional clinical programs, the charges shall be as listed below.
Clinical Programs. ▪ Maintenance of Preferred Drug List(s) that identifies preferred and non-preferred products. ▪ Cigna Clinical Prior Authorization and Managed Drug List. ▪ Integrated Concurrent Drug Utilization Review (DUR) ▪ Retrospective DUR - a program summarizing physician prescribing patterns ▪ Other clinical programs at Cigna's discretion.
Clinical Programs. As consideration for the clinical Services selected by County in accordance with the Agreement, County will pay to Contractor the fees set forth below:
Clinical Programs. Subject to applicable Law, Member Pharmacy must provide to MedImpact any and all reasonably available information that MedImpact needs to perform clinical programs and services and conduct drug utilization review. Member Pharmacy must support all such clinical programs and services.
Clinical Programs. WellPoint shall develop such clinical/disease management programs as are mutually agreed upon in writing by the Parties, and the revenues from which shall be shared as mutually agreed upon by the Parties in writing. [Confidential Treatment — Intentionally Left Blank]
Clinical Programs. BIOGEN will, at its sole expense, be responsible for the worldwide design and conduct of all pre-clinical, clinical, development and regulatory work under this Agreement for PRODUCTS being developed for sale hereunder and under the BML AGREEMENT, with input from CVT through its representation on the OPERATING COMMITTEE and the Strategy Committee. Notwithstanding the foregoing, CVT shall lead the protocol design and selection of key investigators for the following clinical studies which are in the planning stages as of the Effective Date, subject to BIOGEN's guidance and right of final approval:
Clinical Programs. (i) Establish and implement clinical and special programs, services, practices and procedures deemed appropriate by Manager, and establish and maintain internal policies and procedures and plans of organization for each program;
